Researchers have shown that an inhaled engineered bacterium can reduce drug-resistant bacterial biofilms on breathing tubes in pigs, a large-animal result that moves an experimental “living medicine” closer to the kinds of conditions it would need to meet before human testing.
The study, published in eBioMedicine, focused on Pseudomonas aeruginosa, a bacterium that can form persistent biofilms on the surface of endotracheal tubes used to ventilate hospital patients. These dense communities can be difficult to treat because the biofilm structure helps shield bacteria from antibiotics and other interventions.
A bacterium repurposed as treatment
The experimental therapy uses Mycoplasma pneumoniae, a bacterium normally associated with a mild lung infection. The researchers genetically altered it to be harmless for humans and equipped it with genes intended to attack Pseudomonas biofilms.
The modified organism was designed to deliver two kinds of therapeutic activity. One set of genes produces molecules that dissolve sugars helping hold the biofilm together. Another produces toxins aimed specifically at Pseudomonas aeruginosa. Rather than relying on a conventional drug dose alone, the approach uses a living organism adapted to the lung as a vehicle for therapeutic molecules.
The team describes the concept as part of the emerging field of live biotherapeutics. In this case, the lung-adapted bacterium is reprogrammed to deliver treatment instead of causing harm.
Results in ventilated pigs
In the pig experiment, the treatment was delivered as an inhaled mist through a nebulizer. That detail matters because nebulizers are already familiar medical devices and represent a plausible way to administer an eventual inhaled therapy to patients.
After treatment, the biofilm lining the inside of breathing tubes was thinner. The reported average thickness fell from 6.08 micrometers to 3.67 micrometers, a reduction of about 40%.
Microscope images accompanying the work show the bacterial layer on the interior surface of infected tubes and the corresponding surface after treatment. The study does not establish a human clinical benefit, but it demonstrates that the approach can reach and affect biofilms in a larger animal model.
Why the pig model is significant
The same treatment had previously been shown to tackle biofilms in mice. Pigs offer a more demanding step because their lungs are similar to human lungs in size, structure and immune response. Showing an effect in pigs therefore gives the researchers evidence in a model that is more relevant to the environment in which a future inhaled therapy would need to operate.
Ventilator-associated biofilms are a particularly challenging target. An endotracheal tube provides a surface where bacteria can build up while a patient is receiving respiratory support. When the bacteria involved are antibiotic-resistant, the challenge can be even greater.
Pseudomonas aeruginosa is a notable concern in this setting because it is capable of forming robust biofilms and can resist treatment. The experimental therapy is designed around both parts of that problem: disrupting the physical structure of the biofilm and directing antibacterial toxins at the organism inside it.
What the study does and does not show
The result is an early preclinical finding, not evidence that the therapy is ready for routine medical care. The experiment measured a reduction in biofilm thickness in pig breathing tubes; it did not demonstrate safety or effectiveness in people, nor does it show that the treatment prevents infections or improves outcomes for ventilated patients.
Still, the study establishes two practical milestones. First, the engineered bacterium worked against the target biofilm in a large animal. Second, it was administered through a nebulizer, a route compatible with how an inhaled product could potentially be delivered in a clinical setting.
Those milestones matter because live biotherapeutics must solve problems beyond laboratory activity. They need to reach the intended site, remain active in a complex biological environment and be delivered by a method that can fit medical practice. The pig study addresses parts of those questions while leaving many others for subsequent research.
A different model for antimicrobial treatment
The work points toward a more targeted model of antimicrobial therapy: using a modified lung bacterium to carry anti-biofilm and antibacterial functions directly to the respiratory environment. If further studies support its safety and performance, such an approach could complement efforts to address infections involving antibiotic-resistant organisms.
For now, the key finding is more limited but meaningful. An engineered bacterium inhaled as a mist thinned drug-resistant Pseudomonas biofilms on ventilator tubes in pigs. That is a tangible advance from mouse experiments and an indication that live biotherapeutics may be able to operate in larger, more human-relevant lung models.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
